Skip to content

Gyre Therapeutics, Inc. GYRE Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$9.86M$5.94M+277%$1.58M-57.8%$3.73M+556%
$672K+2.4%$656K+1.1%$649K+1.2%$641K+19.8%$535K+16.1%
$2.58M-43.8%$4.6M+301%$1.15M+26.6%$906K+78.7%$507K-10.6%
$3.18M$4.68M+124%$2.09M+1,719%-$129K+95.3%
$178K+23.6%$144K-78.4%$668K+161%$256K+110%$122K
-$3.06M-$1.25M+59.0%-$3.04M-255%$1.97M+198%
$21K-93.4%$318K-12.9%$365K-98.4%$22.35M+1,563%$1.34M+39.4%
$431K$3.91M-81.8%$21.45M+564%$3.23M+180%
$3M+152%-$5.77M-244%$4.01M+119%$1.83M+830%-$251K+90.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Gyre Therapeutics, Inc. generate?
Gyre Therapeutics, Inc. (GYRE) generated $9.8M in operating cash flow over the trailing twelve months.
What is Gyre Therapeutics, Inc.'s free cash flow?
After $1.2M of capital expenditures, Gyre Therapeutics, Inc.'s free cash flow was $3.1M over the trailing twelve months, up 142.4% year over year.
Where does Gyre Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.